Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $865.72M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 3.97M
Average 2.58M
VSTM Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Verastem, Inc.NASDAQ: VSTM
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 40.8% from a year ago
Cash & equivalents stood at $165.55M at the end of Q1 FY2026, up 40.8% from a year earlier and down 19.2% from the prior quarter. Over 3 fiscal years it compounded at +39.9% a year.
Context
- Cash & equivalents amounted to 72.7% of total assets at the end of Q1 FY2026, down 16.6 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +40.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 204.99M USD
- Year-over-year change
- +130.8%
- 4-year CAGR
- +76.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 204.99M | +130.8% |
| FY2024 | 2024-12-31 | 88.82M | +14.0% |
| FY2023 | 2023-12-31 | 77.91M | +4.0% |
| FY2022 | 2022-12-31 | 74.93M | +252.6% |
| FY2021 | 2021-12-31 | 21.25M | — |
Cash & Equivalents vs competitors
How VSTM compares with its peers on the latest reported figures
- VSTM's Mar 2026 cash & equivalents of $165.55M is the 2nd highest of the 11 companies compared; the peer median is $49.99M.
- Its year-over-year change of +40.8% is the 3rd highest of 11, against a peer median of +9.3%.
- Cash & equivalents amounts to 72.7% of total assets for VSTM, versus a peer median of 18.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $258.6M | +4.3% | +17.5% | 34.7% | |
| Mar 2026 | $165.55M | +40.8% | +39.9% | 72.7% | |
| Mar 2026 | $88.91M | +45.7% | +15.7% | 40.0% | |
| Mar 2026 | $61.27M | +19.5% | +35.9% | 18.6% | |
| Mar 2026 | $56.4M | +14.3% | -11.9% | 12.9% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $52.66M | +100.9% | — | 12.6% |
| Mar 2026 | $47.32M | +31.9% | +21.0% | 0.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $34.06M | -13.0% | +12.0% | 31.6% |
| Dec 2025 | $23.79M | -60.9% | -17.8% | 69.1% | |
| Mar 2026 | $21.76M | -46.0% | +4.8% | 18.2% | |
| Mar 2026 | $8.54M | -64.5% | +2.2% | 17.4% | |
| Peer median (excluding VSTM) | $49.99M | +9.3% | +12.0% | 18.4% | |
Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21.25M | 74.93M | 77.91M | 88.82M | 204.99M |
| Short-term Investments | 79M | 12.96M | 59.22M | 0 | 0 |
| Net Receivables | 516K | 31K | 0 | 200K | 8.81M |
| Inventory | 0 | 0 | 0 | 0 | 1.83M |
| Other Current Assets | 0 | 0 | 6.55M | 5.94M | 7.78M |
| Total Current Assets | 105.74M | 92.87M | 143.68M | 94.96M | 223.41M |
| Property, Plant & Equipment (Net) | 2.51M | 1.88M | 1.21M | 1.44M | 491K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 16.43M |
| Long-term Investments | 0 | 241K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 410K | 58K | 4.83M | 5.14M | 6.11M |
| Total Non-current Assets | 2.92M | 2.18M | 6.04M | 6.58M | 23.03M |
| Total Assets | 108.66M | 95.05M | 149.72M | 101.54M | 246.44M |
| Account Payables | 2.3M | 4.9M | 7.18M | 4.03M | 12.45M |
| Short-term Debt | 0 | 275K | 0 | 0 | 535K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 710K | 0 | 0 | 0 |
| Other Current Liabilities | 3.89M | 11.14M | 5.12M | 6.25M | 59.29M |
| Total Current Liabilities | 18.59M | 21.66M | 26.38M | 30.97M | 72.27M |
| Long-term Debt | 249K | 24.53M | 40.09M | 40.72M | 76.33M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 25.35M | 58.2M | 40.65M |
| Total Non-current Liabilities | 2.51M | 26M | 65.96M | 99.46M | 116.98M |
| Total Liabilities | 21.1M | 47.66M | 92.34M | 130.43M | 189.25M |
| Common Stock | 19K | 20K | 3K | 4K | 8K |
| Retained Earnings | (663.71M) | (737.52M) | (824.89M) | (955.53M) | (1.16B) |
| Accumulated OCI | 34K | 0 | 13K | 0 | 5.23M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 87.56M | 47.39M | 57.37M | (28.89M) | 57.2M |
| Total Debt | 3.18M | 27.07M | 41.56M | 42.25M | 76.87M |
| Net Debt | (18.07M) | (47.87M) | (36.35M) | (46.56M) | (128.13M) |
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$6.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.